Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) is expected to release its Q2 2025 earnings data before the market opens on Thursday, August 14th. Analysts expect Eledon Pharmaceuticals to post earnings of ($0.23) per share for the quarter.
Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) last posted its earnings results on Thursday, August 14th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.10. On average, analysts expect Eledon Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Eledon Pharmaceuticals Stock Down 0.4%
Shares of NASDAQ ELDN traded down $0.01 during midday trading on Friday, reaching $2.59. 214,561 shares of the company were exchanged, compared to its average volume of 411,052. The stock's 50-day moving average price is $3.12 and its 200-day moving average price is $3.39. The stock has a market cap of $155.09 million, a P/E ratio of -1.23 and a beta of -0.15. Eledon Pharmaceuticals has a one year low of $2.38 and a one year high of $5.54.
Wall Street Analyst Weigh In
A number of analysts have weighed in on ELDN shares. Craig Hallum started coverage on shares of Eledon Pharmaceuticals in a research note on Friday, July 25th. They set a "buy" rating and a $12.00 target price on the stock. Wall Street Zen cut shares of Eledon Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Friday, June 6th. Finally, HC Wainwright raised shares of Eledon Pharmaceuticals to a "buy" rating and set a $9.00 target price on the stock in a research note on Wednesday, June 18th.
Read Our Latest Stock Report on ELDN
Institutional Trading of Eledon Pharmaceuticals
Institutional investors have recently modified their holdings of the business. Bank of America Corp DE grew its stake in shares of Eledon Pharmaceuticals by 261.8% in the second quarter. Bank of America Corp DE now owns 25,367 shares of the company's stock worth $69,000 after purchasing an additional 18,355 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in Eledon Pharmaceuticals in the second quarter valued at $75,000. Invesco Ltd. acquired a new position in Eledon Pharmaceuticals in the second quarter valued at $81,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Eledon Pharmaceuticals in the second quarter valued at $87,000. Finally, American Century Companies Inc. acquired a new position in Eledon Pharmaceuticals in the second quarter valued at $96,000. Institutional investors own 56.77% of the company's stock.
About Eledon Pharmaceuticals
(
Get Free Report)
Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).
Featured Articles
Before you consider Eledon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eledon Pharmaceuticals wasn't on the list.
While Eledon Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
